On June 5, 2023, GlobalSkin, in collaboration with Cardiff University (UK) and University Medical Centre Hamburg-Eppendorf (Germany), launched the Global Research on the Impact of Dermatological Diseases (GRIDD) Study. The GRIDD Study is a ground-breaking initiative aimed at generating comprehensive global data about the real impact of conditions of the skin, hair, nails, and mucosa. At the heart of this study is the first use of the new Patient-Reported Impact of Dermatological Diseases (PRIDD) measure, a tool developed with nearly 2500 dermatology patients to capture and quantify unique patient perspectives. Launched with the aim of engaging 10,000 participants, the GRIDD Study takes 10-20 minutes to complete and is accessible in the following 17 languages. Thanks to our Member community, the patient response to the study in the first three weeks has been extremely encouraging. As of June 25, 2023, the survey has been taken by 861 individuals from 46 countries and 62 different disease areas. Lichen Sclerosis leads as the condition with the most responses (23%), followed by Psoriasis (13%) and Hidradenitis Suppurativa (11%). GlobalSkin Members and stakeholders in dermatology including health care professionals can play a vital role in the success of the GRIDD Study by encouraging patient participation. The data collected will help to validate the need for improved care, better treatment options, and more affordable medicine for dermatology patients globally. The GRIDD Study is open until September 28, 2023. If you are a dermatology patient – you are invited to take the GRIDD Survey now and share it with anyone who can take part! |